The Executive Order: Rhetoric Versus Reality
As the world continues to grapple with the aftermath of the COVID-19 pandemic, President Donald Trump has signed an executive order barring federal funding for gain-of-function research—scientific studies that alter pathogens to enhance their transmissibility or virulence—in countries deemed to have “poor oversight,” notably China and Iran. The White House frames this as a bold, sweeping measure to keep Americans safe from future pandemics. Yet a closer look at the order reveals a policy far narrower than supporters herald and critics feared—a move more symbolic than substantive, with potential wide-ranging consequences for the global scientific community.
Set against the backdrop of persistent suspicion about the origin of COVID-19 and fevered speculation tying it to research at the Wuhan Institute of Virology, Trump’s executive order plays directly into the narrative advanced by his administration: foreign biosecurity threats justify a clampdown on overseas scientific collaboration. According to a Reuters report, the ban is intended “to drastically reduce the potential for lab-related incidents involving gain-of-function research, like that conducted on bat coronaviruses in China.” This aligns with a newly launched federal COVID-19 web page that doubles down on assertions—so far unproven—that the pandemic was sparked by such research in Wuhan.
The executive order, crafted by National Security Council pandemic policy director Gerry Parker, specifically targets foreign research funding. While early drafts hinted at a far broader crackdown—including a halt to similar research within the United States—the final order pulls its punches. It focuses on withholding U.S. dollars from certain labs abroad, tasking federal agencies to revise guidance and compliance requirements for grant recipients. Notably, the National Institutes of Health (NIH) immediately responded by announcing it will cease all foreign subawards, further tightening the purse strings on U.S.-funded scientific projects overseas.
Security, Science, and Political Theater
The arc of American policy on gain-of-function research has always reflected a tug-of-war between biosecurity—and the real risks of lab mishaps—and the needs of scientific progress. The order’s language and timing echo longstanding conservative anxieties about American tax dollars funding science in “hostile” countries. Dr. Anthony Fauci and the NIH, who previously presided over funding streams to the Wuhan laboratory (including $1.4 million via USAID, according to The Washington Post), have become political punching bags for a right wing determined to score points on pandemic blame and borderless science.
Science thrives on global collaboration, especially in fields like virology, where diseases ignore national boundaries. The failure of the Trump administration to consult widely with public health and research experts—opting instead for a uniliteral ban—raises red flags. Harvard epidemiologist Dr. Marc Lipsitch, an outspoken critic of risky gain-of-function work but also of political overreach, noted in a 2019 interview with NPR that “bans done poorly can drive dangerous research underground,” making oversight less effective, not more.
“A poorly framed ban risks freezing legitimate research and shoving risky experiments out of sight, making them harder, not easier, to police.”
Historical parallels illuminate the pitfalls. After the Obama administration issued a moratorium on gain-of-function work in 2014, a patchwork of exceptions and loopholes persisted, slowing critical biomedical research while doing little to reassure a wary public. The Trump order, too, seems poised to repeat that pattern: visible toughness, procedural confusion, and profound uncertainty for American-funded teams working on the frontlines of global infectious disease.
The Cost of Fear-Based Policy
Beyond the headline-grabbing language and campaign trail bravado lies an uncomfortable truth: the ban is less about scientific safety and more about political signaling. Restricting U.S. science agencies from funding international projects may play well with a certain isolationist segment of the electorate, but it comes at the price of hampering global public health preparedness. Pathogens travel. Collaborative international networks—built over decades—are what enabled rapid COVID vaccine development in early 2020. The experience of the Ebola epidemics in West Africa and Zika outbreaks in the Americas underscores that shuttering research ties abroad can leave the world, including the United States, more vulnerable, not less.
Expert voices are increasingly anxious about this drift. Dr. Angela Rasmussen, a virologist now at the Vaccine and Infectious Disease Organization, warned in Nature last year that “blanket bans on international research funding undermine the trust and transparency needed for global pandemic preparedness.” What happens when American scientists can no longer train, supervise, or audit research conducted by foreign labs? As the Nobel-winning molecular biologist Harold Varmus once remarked, “You want to be in the tent, not just spying over the fence.”
Complexities abound. The Trump order directs the Office of Science and Technology Policy and the national security adviser to establish new standards for identifying “potentially risky studies” in the coming year. Until then, critical research on vaccine platforms, diagnostics, or even benign viral behavior could be snarled in bureaucratic purgatory. The U.S. Agency for International Development (USAID), already gutted by staffing cuts and contract cancellations under Trump, will watch as crucial programs in pandemic early warning and global outbreak response quietly wither.
Who benefits when American science retreats from the world stage? Clearly not the average citizen, who relies on timely breakthroughs to fend off the next virus. Nor do the world’s most vulnerable—communities where emerging pathogens often first spill over from animals to humans, and where first detection means first defense.
The Way Forward: Science, Not Scapegoating
Are there real risks to gain-of-function research? Absolutely. The biosafety lapses of past years—from China to the Netherlands to the United States—have shown that ambitious scientists sometimes overstep, and oversight must be vigilant, transparent, and science-led. But effective governance isn’t built on blunt bans and blame-casting. It emerges from international standards, robust peer review, and open cross-border exchange.
Political theater makes a poor substitute for sound policy. By shifting focus away from nuanced risk assessment and toward an adversarial posture, Trump’s executive order risks alienating allies and undermining the very biosecurity it claims to strengthen. It is a cautionary tale for progressives and centrists alike: the antidote to anxiety-ridden science policy is not retreat, but leadership—worldly, evidence-based, and engaged. America cannot afford to cede the frontlines of biomedical innovation to authoritarian rivals or let fear trump reasoned judgment. Our collective well-being depends on it.
